Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung

Lei Yang1,2, Yun-Ting He1, Song Dong1

  • 1Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.

Abstract

Insights

Immunotherapy is less effective in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) due to a lack of CD8+ tissue-resident memory (TRM) cells. This deficiency in EGFR-mutant lung adenocarcinoma (LUAD) creates a suppressive tumor microenvironment (TME).

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Immunotherapy efficacy is limited in patients with EGFR-mutant NSCLC, often linked to low PD-L1 and TMB.
  • The tumor microenvironment (TME) in EGFR-mutant NSCLC is not fully understood, impacting immunotherapy response.
  • EGFR mutations are common in lung adenocarcinoma (LUAD), a major subtype of NSCLC.

Purpose of the Study:

  • To comprehensively characterize the TME of EGFR-mutant LUAD at a single-cell level.
  • To elucidate the cellular composition and functional aspects of the immune landscape in EGFR-mutant LUAD.
  • To identify factors contributing to immunotherapy resistance in this patient subgroup.

Main Methods:

  • Single-cell transcriptome sequencing and multiplex immunohistochemistry were employed.
  • Immune microenvironments of EGFR-mutant and wild-type LUADs were investigated.
  • Bioinformatic analysis compared single cells from treatment-naïve and post-immunotherapy samples.

Main Results:

  • EGFR-mutant LUAD exhibited a deficiency in CD8+ tissue-resident memory (TRM) cells, crucial for tertiary lymphoid structures.
  • Tumor-associated macrophages and cancer-associated fibroblasts, important for CD8+ TRM recruitment, were also reduced.
  • Reduced immune checkpoint crosstalk (PD-1/PD-L1) was observed in EGFR-mutant LUAD compared to wild-type.

Conclusions:

  • Lack of CD8+ TRM cells is a key factor in the suppressive TME of EGFR-mutant LUAD.
  • Cellular components influencing CD8+ TRM function may negatively impact the TME in EGFR-mutant LUAD.
  • Understanding the single-cell immune landscape is crucial for improving immunotherapy for EGFR-mutant LUAD.